Ganapathy Karthikeyan

2 papers in the library · 23 citations · publishing 2022-2024

Papers

Sort Most recent Most cited

IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression.

Psychiatry Research October 1, 2024 Gilmar Gutierrez, Jennifer Swainson, Nisha Ravindran et al. 17 citations

Intravenous (IV) ketamine and intranasal (IN) esketamine are novel therapies to manage treatment resistant depression within major depressive disorder (MDD-TRD). This is a multi-site observational study aiming to assess the real-world effectiveness and tolerability of these novel therapies in the management of MDD-TRD. 53 patients were referred to receive IV ketamine (n = 26, 69.23 % female,...

DOI: 10.1016/j.psychres.2024.116125 Full text Major depressive disorder Antidepressant effect Depressive symptoms Psychopharmacology +8

Association of intranasal esketamine, a novel ‘standard of care’ treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice

BMJ Open September 1, 2022 Gustavo Vazquez, Gilmar Gutierrez, Joshua D. Rosenblat et al. 6 citations

INTRODUCTION: Esketamine is the S-enantiomer of racemic ketamine and has been approved by the Food and Drug Administration for the management of treatment resistant depression, demonstrating effective and long-lasting benefits. The objective of this observational study is to elucidate the association of intranasal (IN) esketamine with beneficial and negative outcomes in the management of...

DOI: 10.1136/bmjopen-2022-060967 Full text